Differentiation of solid and cystic small renal masses: the role of multiphase CT markers in predicting malignant histology, subtype, and grade.

PURPOSE: This study aimed to assess the diagnostic performance of multiphase contrast-enhanced computed tomography (MCECT) in differentiating benign and malignant solid and cystic small renal masses (SRMs), predicting histologic subtypes, and grading, using signal intensity (SI) and tumour-to-cortex signal intensity (TCSI) ratio.

MATERIAL AND

METHODS

A retrospective analysis was conducted on 181 patients with solid and cystic SRMs (≤ 4 cm). MCECT imaging across 4 phases (non-contrast, corticomedullary, nephrographic, and excretory) was performed. SI and TCSI values were measured, and their diagnostic performance was evaluated using receiver operating characteristic (ROC) analysis. Solid, Bosniak IIF, III, and IV SRMs underwent histopathological confirmation.

RESULTS

Among solid SRMs, excretory phase SI achieved an area under the curve (AUC) of 0.848 for differentiating RCC from other SRMs, with 100% sensitivity and 61.3% specificity. For distinguishing renal cell carcinoma (RCC) from benign SRMs, the most effective parameter was the TCSI ratio obtained from computed tomography excretory phase (88.6% sensitivity, 52.4% specificity, 0.763 AUC). For Bosniak IIF cysts, the corticomedullary phase SI provided an AUC of 0.902, with 93% sensitivity and 87.5% specificity. RCC subtyping showed distinct SI characteristics across phases, particularly for clear cell RCC. Nephrographic phase SI differentiated low- versus high-grade RCC, with an AUC of 0.901, 90.2% sensitivity, and 86.4% specificity.

CONCLUSIONS

MCECT-derived imaging biomarkers, particularly SI and TCSI, are effective non-invasive tools for characterising SRMs, aiding in the differentiation of benign and malignant lesions, histological subtypes, and tumour grades. Their integration with advanced radiomics could further enhance diagnostic accuracy.